129 related articles for article (PubMed ID: 30739341)
1. A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis.
Saigusa R; Yamashita T; Miura S; Hirabayashi M; Nakamura K; Miyagawa T; Fukui Y; Yoshizaki A; Sato S; Asano Y
Exp Dermatol; 2019 May; 28(5):536-542. PubMed ID: 30739341
[TBL] [Abstract][Full Text] [Related]
2. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
[TBL] [Abstract][Full Text] [Related]
3. Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions.
Saigusa R; Asano Y; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
Br J Dermatol; 2016 Feb; 174(2):338-47. PubMed ID: 26399195
[TBL] [Abstract][Full Text] [Related]
4. Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis.
Stochmal A; Czuwara J; Zaremba M; Rudnicka L
Arch Dermatol Res; 2020 Aug; 312(6):453-458. PubMed ID: 31667578
[TBL] [Abstract][Full Text] [Related]
5. Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency.
Saigusa R; Asano Y; Nakamura K; Hirabayashi M; Miura S; Yamashita T; Taniguchi T; Ichimura Y; Takahashi T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
J Invest Dermatol; 2017 Sep; 137(9):1850-1859. PubMed ID: 28528914
[TBL] [Abstract][Full Text] [Related]
6. Correlation between diffuse pigmentation and keratinocyte-derived endothelin-1 in systemic sclerosis.
Tabata H; Hara N; Otsuka S; Yamakage A; Yamazaki S; Koibuchi N
Int J Dermatol; 2000 Dec; 39(12):899-902. PubMed ID: 11168657
[TBL] [Abstract][Full Text] [Related]
7. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.
Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
[TBL] [Abstract][Full Text] [Related]
9. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis.
Noda S; Asano Y; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
PLoS One; 2012; 7(2):e32272. PubMed ID: 22384200
[TBL] [Abstract][Full Text] [Related]
10. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.
Takahashi T; Asano Y; Noda S; Aozasa N; Akamata K; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Br J Dermatol; 2015 Sep; 173(3):681-9. PubMed ID: 25781362
[TBL] [Abstract][Full Text] [Related]
11. A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis.
Awaji K; Miyagawa T; Fukui Y; Toyama S; Omatsu J; Norimatsu Y; Ikawa T; Watanabe Y; Yoshizaki A; Sato S; Asano Y
Exp Dermatol; 2021 Jul; 30(7):959-965. PubMed ID: 33719171
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Serum Galectin-9 and Soluble CD155 Levels in Patients with Systemic Sclerosis.
Chihara M; Kurita M; Yoshihara Y; Asahina A; Yanaba K
J Immunol Res; 2018; 2018():9473243. PubMed ID: 30599005
[TBL] [Abstract][Full Text] [Related]
14. Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts.
Cutolo M; Montagna P; Brizzolara R; Smith V; Alessandri E; Villaggio B; Sulli A; Tavilla PP; Pizzorni C; Soldano S
J Rheumatol; 2015 Mar; 42(3):456-63. PubMed ID: 25593238
[TBL] [Abstract][Full Text] [Related]
15. Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy.
Yanaba K; Asano Y; Akamata K; Noda S; Aozasa N; Taniguchi T; Takahashi T; Toyama T; Ichimura Y; Sumida H; Kuwano Y; Miyazaki M; Sato S
Int J Rheum Dis; 2016 Jun; 19(6):622-7. PubMed ID: 24517166
[TBL] [Abstract][Full Text] [Related]
16. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.
Manetti M; Guiducci S; Romano E; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2012 Jun; 71(6):1064-72. PubMed ID: 22258486
[TBL] [Abstract][Full Text] [Related]
17. Dysfunctional Keratinocytes Increase Dermal Inflammation in Systemic Sclerosis: Results From Studies Using Tissue-Engineered Scleroderma Epidermis.
Russo B; Borowczyk J; Boehncke WH; Truchetet ME; Modarressi A; Brembilla NC; Chizzolini C
Arthritis Rheumatol; 2021 Jul; 73(7):1311-1317. PubMed ID: 33497035
[TBL] [Abstract][Full Text] [Related]
18. Galectin-1 and Galectin-3 Expression in Lesional Skin of Patients With Systemic Sclerosis-Association With Disease Severity.
Mora GF; Zubieta MR
J Clin Rheumatol; 2021 Dec; 27(8):317-323. PubMed ID: 32501939
[TBL] [Abstract][Full Text] [Related]
19. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.
Noda S; Asano Y; Takahashi T; Akamata K; Aozasa N; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
Rheumatology (Oxford); 2013 May; 52(5):790-9. PubMed ID: 23287360
[TBL] [Abstract][Full Text] [Related]
20. Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.
Miyagawa T; Taniguchi T; Saigusa R; Fukayama M; Takahashi T; Yamashita T; Hirabayashi M; Miura S; Nakamura K; Yoshizaki A; Sato S; Asano Y
Rheumatology (Oxford); 2020 Aug; 59(8):2005-2015. PubMed ID: 31782787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
